Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service
Catalent has expanded its integrated development, manufacturing and supply solution, OneBio Suite, across a range of biologic modalities, including antibody and recombinant proteins, cell and gene therapies, and mRNA.
The launch of the expanded offering will coincide with Catalent exhibiting at the BIO International Convention (booth 785), which takes place at the Boston Convention & Exhibition Centre, from June 5-8, 2023.
Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service to accelerate programs from development to manufacturing, including fill/finish and packaging, and support for clinical supply and commercial launch.
Under the newly expanded OneBio offering, customers will continue to benefit from an integrated contract and proposal, harmonised project management, a global development and manufacturing network, and diverse expertise, now across biologic modalities and service offerings.
“Since its launch, we have been able to demonstrate how beneficial the OneBio integrated biologics development solution can be to sponsors, saving them time on managing multiple partners, and handoffs between companies,” said Karen Flynn, Catalent’s Interim President, Division Head for BioModalities (Cell, Gene and Protein Therapies).
Since its launch, we have been able to demonstrate how beneficial the OneBio integrated biologics development solution can be to sponsors
And for early-stage customers that need to develop and/or optimise their process towards GMP manufacturing, Catalent’s OneBio offering will include multi-modality, turn-key platforms aimed to provide speed to clinical trial supply under the UpTempoSM brand.
At the BIO International Convention, Carey Connolly, PhD, Catalent’s Senior Director, Process Development, will present ‘One-Stop Integrated Viral Vector Platform for Speed to Clinic’ on Tuesday, June 5 at the BioProcess International Theatre.
In her talk, Dr Connolly will detail the integrated services within the UpTempo AAV development platform and the use of standardised protocols for cell culture, transfection, and downstream purification to save time, as well as the advantages it now has with an in-house, clonal HEK293 cell line, and off-the-shelf plasmids to support a robust supply chain.
Originally launched in 2022, the UpTempo AAV platform was expanded in March of 2023 to include Catalent’s own HEK293 producer cell line and off-the-shelf plasmids, including pHelper and rep/cap. Additional UpTempo platforms will follow for other modalities.
Catalent experts will be available to discuss other recent advancements across the biologics segment, including high-speed syringe filling line investments at its sites in Anagni, Italy, and Bloomington, Indiana.
In addition, Catalent Biologics’ European drug product network also recently saw the completion of upgrades to its site in Limoges, France, making it the company’s European centre-of-excellence for early-phase clinical and small-scale commercial biologics formulation development and drug product fill/finish.